SCHLAGWORTE: Martin Krauss
The era of outsourcing in biotech
Modern drug development is an inherently complex under-taking: bringing a new therapy from discovery to market requires highly specialised expertise, cutting-edge infrastructure, regulatory know-how,...
Brussels‘ biotech offensive: an overdue signal with flaws
Together with leading chinical research and legal experts, we analyse: is Brussels' 75-day fast-track enough to stop the innovation drain, or does the lack...
FGK Clinical Research expands to the Netherlands
FGK Clinical Research is strengthening its European footprint with an operational presence in the Netherlands. The Munich-headquartered contract research organisation (CRO) is expanding its...
„Für 2026 erwarten wir, dass technologische Innovationen in klinischen Studien weiter...
Der Jahresauftakt steht im Zeichen eines vorsichtigen, aber spürbaren Stimmungsumschwungs. Nach Jahren permanenter Krisenrhetorik und wirtschaftlicher Verwerfungen wächst in der Branche die Erwartung, dass...